FOLD · AMICUS THERAPEUTICS, INC.
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-04-27 | MCGLYNN MARGARET G |
Director |
Other↓
Filing footnotes — Common Stock (Direct)
The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 31,000 shares of Common Stock and 63,631 restricted stock units (which vested in full in connection with consummation of the Merger). |
Common Stock
|
94,631 |
| 2026-04-27 | WHITMAN BURKE W |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
25,964 |
| 2026-04-27 | SBLENDORIO GLENN |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
36,111 |
| 2026-04-27 | RAAB MICHAEL |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option vested in full in connection with consummation of the Merger. |
Stock Options (right to buy)
|
74,872 |
| 2026-04-27 | Bleil Lynn Dorsey |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
45,423 |
| 2026-04-27 | Clark David Michael |
Chief People Officer |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option vested in full in connection with consummation of the Merger. |
Stock Options (right to buy)
|
105,388 |
| 2026-04-27 | MCGLYNN MARGARET G |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
19,473 |
| 2026-04-27 | SBLENDORIO GLENN |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option vested in full in connection with consummation of the Merger. |
Stock Options (right to buy)
|
74,872 |
| 2026-04-27 | WHEELER CRAIG A |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
42,467 |
| 2026-04-27 | RAAB MICHAEL |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
20,000 |
| 2026-04-27 | WHITMAN BURKE W |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
45,423 |
| 2026-04-27 | MCGLYNN MARGARET G |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
20,000 |
| 2026-04-27 | ROBERTS EIRY |
Chief Medical Officer |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option vested in full in connection with consummation of the Merger. |
Stock Options (right to buy)
|
74,872 |
| 2026-04-27 | ROBERTS EIRY |
Chief Medical Officer |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
30,474 |
| 2026-04-27 | MCGLYNN MARGARET G |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option vested in full in connection with consummation of the Merger. |
Stock Options (right to buy)
|
74,872 |
| 2026-04-27 | Kelly Michael Aaron |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option vested in full in connection with consummation of the Merger. |
Stock Options (right to buy)
|
74,872 |
| 2026-04-27 | Harford Simon N.R. |
Chief Financial Officer |
Other↓
Filing footnotes — Common Stock (Direct)
The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 108,478 shares of Common Stock and 35,117 restricted stock units (which vested in full in connection with consummation of the Merger). |
Common Stock
|
143,595 |
| 2026-04-27 | WHITMAN BURKE W |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
18,574 |
| 2026-04-27 | Castelli Jeff |
Chief Development Officer |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option vested in full in connection with consummation of the Merger. |
Stock Options (right to buy)
|
99,073 |
| 2026-04-27 | WHEELER CRAIG A |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
16,236 |
| 2026-04-27 | WHITMAN BURKE W |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
30,474 |
| 2026-04-27 | Rosenberg Ellen |
Chief Legal Officer |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
93,663 |
| 2026-04-27 | ROBERTS EIRY |
Chief Medical Officer |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
45,423 |
| 2026-04-27 | WHEELER CRAIG A |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
30,000 |
| 2026-04-27 | Campbell Bradley L |
Director, President and CEO |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option vested in full in connection with consummation of the Merger. |
Stock Options (right to buy)
|
482,908 |
| 2026-04-27 | Clark David Michael |
Chief People Officer |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
77,134 |
| 2026-04-27 | Campbell Bradley L |
Director, President and CEO |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option vested in full in connection with consummation of the Merger. |
Stock Options (right to buy)
|
301,109 |
| 2026-04-27 | Campbell Bradley L |
Director, President and CEO |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
151,515 |
| 2026-04-27 | Kelly Michael Aaron |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
36,111 |
| 2026-04-27 | Clark David Michael |
Chief People Officer |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
84,842 |
| 2026-04-27 | MCGLYNN MARGARET G |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
18,574 |
| 2026-04-27 | Campbell Bradley L |
Director, President and CEO |
Other↓
Filing footnotes — Common Stock (Direct)
The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 689,467 shares of Common Stock and 319,213 restricted stock units (which vested in full in connection with consummation of the Merger). |
Common Stock
|
1,008,680 |
| 2026-04-27 | WHEELER CRAIG A |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
45,423 |
| 2026-04-27 | Prout Samantha |
Chief Accounting Officer |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option vested in full in connection with consummation of the Merger. |
Stock Options (right to buy)
|
55,203 |
| 2026-04-27 | Bleil Lynn Dorsey |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
19,473 |
| 2026-04-27 | SBLENDORIO GLENN |
Director |
Other↓
Filing footnotes — Common Stock (Direct)
The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 122,150 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger). |
Common Stock
|
142,564 |
| 2026-04-27 | SBLENDORIO GLENN |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
20,000 |
| 2026-04-27 | ROBERTS EIRY |
Chief Medical Officer |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
40,625 |
| 2026-04-27 | WHEELER CRAIG A |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
19,473 |
| 2026-04-27 | Rosenberg Ellen |
Chief Legal Officer |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option vested in full in connection with consummation of the Merger. |
Stock Options (right to buy)
|
108,980 |
| 2026-04-27 | Clark David Michael |
Chief People Officer |
Other↓
Filing footnotes — Common Stock (Direct)
The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 130,942 shares of Common Stock and 90,869 restricted stock units (which vested in full in connection with consummation of the Merger). |
Common Stock
|
221,811 |
| 2026-04-27 | Castelli Jeff |
Chief Development Officer |
Other↓
Filing footnotes — Common Stock (Direct)
The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 318,417 shares of Common Stock and 108,672 restricted stock units (which vested in full in connection with consummation of the Merger). |
Common Stock
|
427,089 |
| 2026-04-27 | Castelli Jeff |
Chief Development Officer |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
108,266 |
| 2026-04-27 | MCGLYNN MARGARET G |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
16,236 |
| 2026-04-27 | Rosenberg Ellen |
Chief Legal Officer |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option vested in full in connection with consummation of the Merger. |
Stock Options (right to buy)
|
203,825 |
| 2026-04-27 | Campbell Bradley L |
Director, President and CEO |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option vested in full in connection with consummation of the Merger. |
Stock Options (right to buy)
|
265,517 |
| 2026-04-27 | ROBERTS EIRY |
Chief Medical Officer |
Other↓
Filing footnotes — Common Stock (Direct)
The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 55,861 shares of Common Stock and 20,414 restricted stock units (which vested in full in connection with consummation of the Merger). |
Common Stock
|
76,275 |
| 2026-04-27 | WHEELER CRAIG A |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
18,574 |
| 2026-04-27 | Prout Samantha |
Chief Accounting Officer |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. |
Stock Options (right to buy)
|
37,810 |
| 2026-04-27 | Bleil Lynn Dorsey |
Director |
Other↓
Filing footnotes — Stock Options (right to buy) (Direct)
In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option vested in full in connection with consummation of the Merger. |
Stock Options (right to buy)
|
74,872 |